CG Oncology's stock has dropped 40% since its IPO peak, driven by profit-taking and competitive concerns despite promising ...

Cancer is a multifactorial disease that affects millions of individuals worldwide and has a profound impact on public health. The heterogeneity of solid ...

In a report released today, Thomas Flaten from Lake Street maintained a Buy rating on Castle Biosciences (CSTL – Research Report), with a price ...

Scotiabank analyst Sung Ji Nam maintained a Buy rating on Castle Biosciences (CSTL – Research Report) today and set a price target of $44.00.

Genascence Corporation ("Genascence"), a clinical-stage biotechnology company revolutionizing the treatment of prevalent musculoskeletal diseases with ...